MarketCap
Facebook
X
TelegramQuarterly report 2025-Q2
added 07-29-2025
Alkermes plc Total Assets 2011-2025 | ALKS
Total Assets — these are all the resources owned by the business that have economic value. They are used to operate the business, generate profit, and ensure the company’s stability.Main categories of assets
Current assets (used within one year):
- Cash and cash equivalents
- Accounts receivable (amounts owed by customers)
- Inventory of goods, raw materials, and supplies
- Short-term investments
- Fixed assets (buildings, machinery, equipment)
- Intangible assets (brands, patents, software)
- Long-term investments
- Goodwill (reputational value from mergers)
Assets represent an objective measure of a business's value, reflecting everything behind it: physical infrastructure, technology, customer base, and financial resources. A high share of liquid assets such as cash indicates a company’s financial flexibility and its ability to maintain stability in changing market conditions.
Asset analysis helps assess how effectively a company utilizes its resources to generate revenue and profit, reflecting its operational efficiency and ability to convert invested capital into financial results.
Annual Total Assets Alkermes plc
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2.06 B | 2.14 B | 1.96 B | 2.02 B | 1.95 B | 1.81 B | 1.83 B | 1.8 B | 1.73 B | 1.86 B | 1.92 B | 1.47 B | 1.44 B | 452 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 2.14 B | 452 M | 1.74 B |
Quarterly Total Assets Alkermes plc
| 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2.25 B | 2.08 B | 2.06 B | 2.16 B | 2.21 B | 2.12 B | 2.14 B | 2.28 B | 2.19 B | 1.92 B | 1.96 B | 1.94 B | - | 1.98 B | 2.02 B | 2 B | 1.94 B | 1.88 B | 1.95 B | 1.95 B | 1.95 B | 1.95 B | 1.81 B | 1.81 B | 1.81 B | 1.81 B | 1.83 B | 1.83 B | 1.83 B | 1.83 B | 1.8 B | 1.8 B | 1.8 B | 1.8 B | 1.73 B | 1.73 B | 1.73 B | 1.73 B | 1.86 B | 1.86 B | 1.86 B | 1.86 B | 1.92 B | 1.92 B | 1.92 B | 1.92 B | 1.58 B | 1.58 B | 1.58 B | 1.58 B | 1.41 B | 1.37 B | 1.45 B | 1.44 B | 1.51 B | 1.5 B | - | 452 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 2.28 B | 452 M | 1.82 B |
Total Assets of other stocks in the Biotechnology industry
| Issuer | Total Assets | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
2.03 B | - | 2.43 % | $ 254 M |  Germany |
 |
Arbutus Biopharma Corporation
ABUS
|
144 M | $ 4.75 | -0.84 % | $ 788 M |  Canada |
 |
Aclaris Therapeutics
ACRS
|
220 M | $ 3.02 | -0.66 % | $ 233 M |  USA |
 |
Aeglea BioTherapeutics
AGLE
|
608 M | - | - | $ 1.01 B | USA |
 |
Alpine Immune Sciences
ALPN
|
287 M | - | - | $ 2.17 B | USA |
 |
AlloVir
ALVR
|
119 M | - | 4.14 % | $ 49.1 M | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
18.1 B | - | - | $ 40.3 B | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
9.12 M | $ 0.22 | 23.66 % | $ 479 M |  Israel |
 |
Aptorum Group Limited
APM
|
16.1 M | $ 1.16 | -1.28 % | $ 6.33 M |  China |
 |
Ampio Pharmaceuticals
AMPE
|
5.74 M | - | -11.43 % | $ 502 K | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
15.2 M | - | -1.52 % | $ 24.7 M | USA |
 |
Applied Molecular Transport
AMTI
|
107 M | - | - | $ 10.1 M | USA |
 |
Midatech Pharma plc
MTP
|
14.8 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Ascendis Pharma A/S
ASND
|
1.18 B | $ 209.08 | -1.75 % | $ 5 B |  Danmark |
 |
Celldex Therapeutics
CLDX
|
792 M | $ 26.17 | -2.46 % | $ 1.69 M | USA |
 |
Aptevo Therapeutics
APVO
|
15.6 M | $ 0.56 | -40.06 % | $ 155 K | USA |
 |
Cellectar Biosciences
CLRB
|
12.1 M | $ 2.6 | -5.8 % | $ 31.8 M | USA |
 |
Alterity Therapeutics Limited
ATHE
|
41.4 M | $ 3.15 | 1.78 % | $ 7.58 B |  Australia |
 |
Biophytis SA
BPTS
|
12 M | - | -13.47 % | $ 169 M |  France |
 |
BioVie
BIVI
|
21.6 M | $ 1.18 | -7.48 % | $ 1.74 M | USA |
 |
Athersys
ATHX
|
60.2 M | - | 3.77 % | $ 22.4 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
1.51 B | - | - | - |  Russia |
 |
Avenue Therapeutics
ATXI
|
2.67 M | - | -52.27 % | $ 4.45 M | USA |
 |
ARCA biopharma
ABIO
|
396 M | - | 1052.0 % | $ 415 M | USA |
 |
AVROBIO
AVRO
|
101 M | - | 1083.1 % | $ 745 M | USA |
 |
Acasti Pharma
ACST
|
72 M | - | 4.01 % | $ 150 M | Canada |
 |
Adaptimmune Therapeutics plc
ADAP
|
283 M | - | -15.15 % | $ 60.3 M | Britain |
 |
BioDelivery Sciences International
BDSI
|
325 M | - | -4.8 % | $ 255 M | USA |
 |
Albireo Pharma
ALBO
|
302 M | - | -0.23 % | $ 916 M | USA |
 |
BioNTech SE
BNTX
|
22.5 B | $ 94.08 | -1.0 % | $ 27.2 B | Germany |
 |
Amphastar Pharmaceuticals
AMPH
|
1.58 B | $ 26.92 | 0.41 % | $ 1.3 B | USA |
 |
BeiGene, Ltd.
BGNE
|
5.92 B | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Anika Therapeutics
ANIK
|
271 M | $ 9.49 | 0.13 % | $ 139 M | USA |
 |
Bellicum Pharmaceuticals
BLCM
|
23.8 M | - | -9.72 % | $ 5.89 M | USA |
 |
Berkeley Lights
BLI
|
226 M | - | -7.31 % | $ 87 M | USA |
 |
bluebird bio
BLUE
|
619 M | - | - | $ 546 M | USA |
 |
Dynavax Technologies Corporation
DVAX
|
986 M | $ 15.4 | 0.1 % | $ 2 B | USA |
 |
Arena Pharmaceuticals
ARNA
|
785 M | - | -6.81 % | $ 3.04 B | USA |
 |
Acer Therapeutics
ACER
|
11.6 M | - | 2.71 % | $ 14 M | USA |
 |
Calithera Biosciences
CALA
|
64.8 M | - | -10.95 % | $ 876 K | USA |
 |
Axon Enterprise
AXON
|
4.47 B | $ 586.59 | -0.77 % | $ 44.4 B | USA |
 |
Ayala Pharmaceuticals
AYLA
|
7.77 M | - | - | $ 7.46 M | Israel |
 |
Eton Pharmaceuticals
ETON
|
31.7 M | $ 16.76 | -1.38 % | $ 430 M | USA |
 |
Evogene Ltd.
EVGN
|
39.9 M | $ 1.03 | -1.9 % | $ 27.9 M | Israel |
 |
Aytu BioScience
AYTU
|
124 M | $ 2.47 | -2.37 % | $ 15.5 M | USA |
 |
AstraZeneca PLC
AZN
|
104 B | $ 92.63 | 0.19 % | $ 96.9 B | Britain |
 |
Exelixis
EXEL
|
2.95 B | $ 46.5 | -0.03 % | $ 13.5 B | USA |
|
Foghorn Therapeutics
FHTX
|
284 M | $ 5.38 | -0.37 % | $ 295 M | USA |
 |
Acorda Therapeutics
ACOR
|
109 M | - | -24.86 % | $ 820 K | USA |
 |
Catalyst Biosciences
CBIO
|
117 M | $ 12.48 | 0.89 % | $ 822 M | USA |